JP2016519651A - 改質された毒素 - Google Patents

改質された毒素 Download PDF

Info

Publication number
JP2016519651A
JP2016519651A JP2016501335A JP2016501335A JP2016519651A JP 2016519651 A JP2016519651 A JP 2016519651A JP 2016501335 A JP2016501335 A JP 2016501335A JP 2016501335 A JP2016501335 A JP 2016501335A JP 2016519651 A JP2016519651 A JP 2016519651A
Authority
JP
Japan
Prior art keywords
amino acid
modified
diphtheria toxin
cell
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016501335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519651A5 (cg-RX-API-DMAC7.html
Inventor
デイビス，クラウド，ジォフレイー
ダッタ，ディープシカ
ベイカー，マシュー，ポール
ラスト，アリソン，ジェーン
キーン，サイモン
Original Assignee
アンジェリカ セラピューティックス，インク．
アンジェリカ セラピューティックス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンジェリカ セラピューティックス，インク．, アンジェリカ セラピューティックス，インク． filed Critical アンジェリカ セラピューティックス，インク．
Publication of JP2016519651A publication Critical patent/JP2016519651A/ja
Publication of JP2016519651A5 publication Critical patent/JP2016519651A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016501335A 2013-03-15 2014-03-11 改質された毒素 Pending JP2016519651A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361799910P 2013-03-15 2013-03-15
US61/799,910 2013-03-15
PCT/US2014/023761 WO2014150600A2 (en) 2013-03-15 2014-03-11 Modified toxins

Publications (2)

Publication Number Publication Date
JP2016519651A true JP2016519651A (ja) 2016-07-07
JP2016519651A5 JP2016519651A5 (cg-RX-API-DMAC7.html) 2017-04-13

Family

ID=51581612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501335A Pending JP2016519651A (ja) 2013-03-15 2014-03-11 改質された毒素

Country Status (6)

Country Link
US (1) US10059750B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968450A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016519651A (cg-RX-API-DMAC7.html)
CA (1) CA2902905A1 (cg-RX-API-DMAC7.html)
HK (1) HK1220376A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014150600A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059750B2 (en) 2013-03-15 2018-08-28 Angelica Therapeutics, Inc. Modified toxins
JP2021516996A (ja) * 2015-09-11 2021-07-15 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生物学的に関連する直交サイトカイン／受容体対

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016204525A1 (ko) * 2015-06-19 2016-12-22 엘지전자(주) 터치 패널 및 표시 장치
US10899829B2 (en) 2016-02-23 2021-01-26 Indiana University Research And Technology Corporation Emapii neutralizing antibody limits influenza A virus (IAV)-induced lung injury
KR20240115933A (ko) * 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
WO2018119114A1 (en) 2016-12-22 2018-06-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018156465A1 (en) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment b as a carrier
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
EP3596118B1 (en) 2017-03-15 2024-08-21 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3787674A4 (en) 2018-04-30 2022-01-26 Merck Sharp & Dohme Corp. PROCESS FOR THE PRODUCTION OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CAPSULAR PROTEIN CONJUGATES FROM LYOSPHERES
US20210252125A1 (en) 2018-04-30 2021-08-19 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
CN111944036B (zh) * 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
US11897930B2 (en) * 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
AU2021272895A1 (en) 2020-05-12 2022-09-22 Cue Biopharma, Inc. Multimeric T-cell modulatory polypeptides and methods of use thereof
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530895A (ja) * 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4830962A (en) 1984-02-09 1989-05-16 Cetus Corporation Recombinant diphtheria toxin fragments
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US5792458A (en) 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
WO1991006667A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
FI923915A7 (fi) 1990-03-02 1992-09-01 Boston Medical Ct Corp Paranettuja kimeerisiä toksiineja
WO1992006117A1 (en) 1990-09-28 1992-04-16 Seragen, Inc. Inhibiting unwanted immune responses
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5695983A (en) 1990-12-18 1997-12-09 The General Hospital Corporation Salmonella vaccines
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
ES2130265T3 (es) 1992-05-06 1999-07-01 Harvard College Region de union al receptor de la toxina difterica.
DE69327534T2 (de) 1992-06-18 2000-06-08 The President And Fellows Of Harvard College, Cambridge Impfstoffe gegen diphtherietoxin
US5856122A (en) 1993-08-24 1999-01-05 University Of Alberta Modification of pertussis toxin
WO1995024483A1 (en) 1994-03-08 1995-09-14 Scotgen Biopharmaceuticals, Inc. Recombinant humanized anti-fb5 antibodies
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
DE4430721A1 (de) 1994-08-30 1996-03-07 Hoechst Ag Autoglanztrocknungsmittel
US5843462A (en) 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
EP0942994B1 (en) 1996-12-09 2005-04-20 Genencor International, Inc. H mutant alpha-amylase enzymes
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US5976806A (en) 1997-06-25 1999-11-02 Pioneer Hi-Bred International, Inc. DNA ligase assay
US6835550B1 (en) 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US6960652B2 (en) 1999-03-30 2005-11-01 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinaceous compounds
AU4057300A (en) 1999-03-30 2000-10-16 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
CA2386237A1 (en) 1999-10-04 2001-04-12 Twinstrand Therapeutics Inc. Improved ricin-like toxins for treatment of cancer
US7368532B2 (en) 1999-12-02 2008-05-06 Syntaxin Limited Constructs for delivery of therapeutic agents to neuronal cells
AU2363301A (en) 1999-12-02 2001-06-12 Thromb-X N.V. Method for reducing the immunogenicity of heterologous proteins by elimination of t-cell epitopes
US20060018885A1 (en) 2000-11-14 2006-01-26 Ildstad Suzanne T Methods for increasing HSC graft efficiency
US20040256304A1 (en) 2001-01-19 2004-12-23 Perry Carlos V. Recirculating filter
CN1514844A (zh) 2001-02-06 2004-07-21 Ĭ��ר�����޹�˾ 免疫原性减弱的经修饰粒细胞集落刺激因子(g-csf)
EP1387856A2 (en) 2001-02-06 2004-02-11 MERCK PATENT GmbH Modified leptin with reduced immunogenicity
WO2002062375A1 (en) 2001-02-06 2002-08-15 Merck Patent Gmbh Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
BR0207015A (pt) 2001-02-06 2004-07-06 Merck Patent Ges Mit Beschroen Eritropoientina modificada (epo) com imunogenicidade reduzida
PL362411A1 (en) 2001-02-06 2004-11-02 Merck Patent Gmbh Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
CA2437270A1 (en) 2001-02-06 2002-08-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified keratinocyte growth factor (kgf) with reduced immunogenicity
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
BR0207283A (pt) 2001-02-19 2004-08-17 Merck Patent Gmbh Anticorpos anti-egfr modificados com imunogenicidade reduzida
CA2438628A1 (en) 2001-02-19 2002-08-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Artificial proteins with reduced immunogenicity
ATE400030T1 (de) 2001-02-19 2008-07-15 Merck Patent Gmbh Methode zur identifizierung von t-zellepitopen und deren anwendung zur herstellung von molekülen mit reduzierter immunogenität
MXPA03007625A (es) 2001-02-26 2003-12-04 Merck Patent Gmbh Trombopoyetina modificada con inmunogenicidad reducida.
PL363181A1 (en) 2001-03-02 2004-11-15 Merck Patent Gmbh Modified interferon alpha with reduced immunogenicity
US20040087503A1 (en) 2001-03-02 2004-05-06 Carr Francis J. Modified ciliary neurotrophic factor (cntf ) with reduced immunogenicity
BR0207905A (pt) 2001-03-08 2004-07-27 Merck Patent Ges Mit Beschroen Protamina modificada com imunogenicidade reduzida
ATE339446T1 (de) 2001-03-08 2006-10-15 Merck Patent Gmbh Modifizierter humaner granulozyten makrophagen kolonien stimulierender faktor (gm-csf) mit reduzierter immunogenität
MXPA03008310A (es) 2001-03-15 2003-12-11 Merck Patent Gmbh Interferon beta modificado con inmunogenicidad reducida.
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
EP2277542B1 (en) 2001-06-01 2014-04-16 Cornell Research Foundation Inc. Modified antibodies to prostrate-specific membrane antigen and uses thereof
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20020197278A1 (en) 2001-06-21 2002-12-26 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
US7087724B2 (en) 2001-06-26 2006-08-08 Agen Biomedical Ltd Carrier molecules
EP1409003A2 (en) 2001-07-13 2004-04-21 MERCK PATENT GmbH Methods for reducing immunogenicity of polypeptides
US20050020494A1 (en) 2001-09-04 2005-01-27 Carr Francis J Modified human growth hormone
HUP0401534A3 (en) 2001-09-04 2006-01-30 Merck Patent Gmbh Modified factor ix
JP4304073B2 (ja) 2001-11-12 2009-07-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 改変された抗ＴＮＦα抗体
US20050074863A1 (en) 2001-11-29 2005-04-07 Koen Hellendoorn T-cell epitodes in carboxypeptidase g2
KR20040101428A (ko) 2002-04-09 2004-12-02 메르크 파텐트 게엠베하 항유전인자형 항-ｃｅａ 항체 분자 및 암백신으로서의이의 용도
KR20040103970A (ko) 2002-04-18 2004-12-09 메르크 파텐트 게엠베하 변형된 펙터 ⅷ
US20050181459A1 (en) 2002-06-11 2005-08-18 Matthew Baker Method for mapping and eliminating T cell epitopes
US20040018568A1 (en) 2002-07-23 2004-01-29 Subhashis Banerjee Methods for detecting deantigenized T cell epitopes and uses thereof
ES2310684T3 (es) 2002-08-09 2009-01-16 Merck Patent Gmbh Epitopes de celulas t en eritropoyetina.
CA2496242A1 (en) 2002-08-21 2004-03-04 Merck Patent Gesellschaft Mit Beschraenkter Haftung T-cell epitopes in staphylococcal enterotoxin b
US7413851B2 (en) 2002-12-13 2008-08-19 Aurelium Biopharma, Inc. Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
CA2512693A1 (en) 2003-01-08 2004-07-29 Xencor, Inc. Novel proteins with altered immunogenicity
CA2523142A1 (en) 2003-04-23 2004-11-04 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
EP1636267A2 (en) 2003-06-26 2006-03-22 MERCK PATENT GmbH Modified hirudin proteins and t-cell epitopes in hirudin
US7541439B2 (en) 2003-06-26 2009-06-02 Merck Patent Gmbh Thrombopoietin proteins with improved properties
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
US20050176028A1 (en) 2003-10-16 2005-08-11 Robert Hofmeister Deimmunized binding molecules to CD3
ATE552276T1 (de) 2003-11-01 2012-04-15 Merck Patent Gmbh Modifizierter anti-cd52-antikörper
US7431720B2 (en) 2003-11-25 2008-10-07 Ethicon, Inc. Multi-function clamping device with stapler and ablation heads
EP2457577A1 (en) 2003-11-25 2012-05-30 Anjin Corporation Diphtheria toxin variant
US20050153872A1 (en) 2004-01-12 2005-07-14 Xiao-Qing Qiu Methods and compositions for the treatment of infection
US20060228404A1 (en) 2004-03-04 2006-10-12 Anderson Daniel G Compositions and methods for treatment of hypertrophic tissues
JP5025460B2 (ja) 2004-03-19 2012-09-12 メルク パテント ゲーエムベーハー 修飾ブーゲニンタンパク質、サイトトキシン、ならびにそれらの方法および使用
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
WO2006044864A2 (en) 2004-10-19 2006-04-27 Duke University Vaccine adjuvant
US20060165687A1 (en) 2004-10-19 2006-07-27 Duke University Vaccine adjuvant
CN1314806C (zh) 2005-01-14 2007-05-09 四川大学 小型化抗eb病毒肿瘤多肽及其应用与制备方法
US20060270600A1 (en) 2005-05-26 2006-11-30 Eisuke Mekada Anti-cancer agents
US20060269514A1 (en) 2005-05-27 2006-11-30 Abdul-Rahman Jazieh Methods and compositions for the modulation of immune responses and cancer diseases
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
US20070250652A1 (en) 2006-04-24 2007-10-25 Atmel Corporation High speed dual-wire communications device requiring no passive pullup components
US8993295B2 (en) 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
US8470314B2 (en) 2008-02-29 2013-06-25 Angelica Therapeutics, Inc. Modified toxins
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
JP2016519651A (ja) 2013-03-15 2016-07-07 アンジェリカ セラピューティックス，インク． 改質された毒素

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530895A (ja) * 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059750B2 (en) 2013-03-15 2018-08-28 Angelica Therapeutics, Inc. Modified toxins
JP2021516996A (ja) * 2015-09-11 2021-07-15 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生物学的に関連する直交サイトカイン／受容体対
US12005079B2 (en) 2015-09-11 2024-06-11 The Board Of Trustees Of The Leland Stanford Junior University Biologically relevant orthogonal cytokine/receptor pairs

Also Published As

Publication number Publication date
US20160009768A1 (en) 2016-01-14
CA2902905A1 (en) 2014-09-25
EP2968450A2 (en) 2016-01-20
WO2014150600A2 (en) 2014-09-25
HK1220376A1 (zh) 2017-05-05
EP2968450A4 (en) 2016-10-26
US10059750B2 (en) 2018-08-28
WO2014150600A3 (en) 2015-05-28
WO2014150600A8 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
JP2016519651A (ja) 改質された毒素
US8470314B2 (en) Modified toxins
JP6188760B2 (ja) 修飾毒素
Korbelik et al. Photodynamic therapy–induced cell surface expression and release of heat shock proteins: relevance for tumor response
JP2019205435A (ja) 特定の細胞型の選択的死滅のための細胞標的化結合領域と志賀毒素ａサブユニット領域とを含む細胞毒性タンパク質
JP4175489B2 (ja) 改変型超抗原と標的探索化合物との結合体及び該結合体の使用
US20110171211A1 (en) Heat shock protein gp96 vaccination and methods of using same
EP3601363B1 (en) Alt-803 in combination with anti-cd38 antibody for cancer therapies
CN114401991A (zh) 用于调节髓系细胞炎性表型的抗siglec-9组合物和方法及其用途
CN114401990A (zh) 用于调节髓系细胞炎性表型的抗psgl-1组合物和方法及其用途
CA3124243A1 (en) Vaccine compositions and methods for restoring nkg2d pathway function against cancers
Jimbo et al. Induction of leukemia‐specific antibodies by immunotherapy with leukemia‐cell‐derived heat shock protein 70
Kaštánková et al. Combined cancer immunotherapy against aurora kinase A
JPWO2019045025A1 (ja) ワクチン組成物
US20220177548A1 (en) Methods and Compositions for Treating Melanoma
HK1143168A (en) Modified toxins
Zheng et al. Heat Shock Protein (HSP)-Based Immunotherapies
Hess Strategic Manipulation of Turmor Antigens to Enhance Immunogenicity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180423

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181204